Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of CMP-CPS-001 in Healthy Volunteers
Sponsor: CAMP4 Therapeutics Corporation
Summary
The objective of this clinical study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of CMP-CPS-001 administered as a subcutaneous injection in adult healthy volunteers.
Official title: A Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study of CMP-CPS-001 in Healthy Volunteers
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
96
Start Date
2024-02-05
Completion Date
2025-08
Last Updated
2025-06-12
Healthy Volunteers
Yes
Conditions
Interventions
CMP-CPS-001
CMP-CPS-001 consists of an antisense oligonucleotide solution that will be administered subcutaneously.
Placebo
Placebo is 0.9% normal saline solution and will be administered subcutaneously.
Locations (1)
Nucleus Network Brisbane (also known as Q-Pharm Pty Ltd)
Herston, Queensland, Australia